Compare · DXCM vs MOBI
DXCM vs MOBI
Side-by-side comparison of DexCom Inc. (DXCM) and Mobia Medical Inc. (MOBI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MOBI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.91B, about 75.7x MOBI ($395.3M).
- DXCM has been more active in the news (15 items in the past 4 weeks vs 5 for MOBI).
- DXCM has more recent analyst coverage (25 ratings vs 0 for MOBI).
- Company
- DexCom Inc.
- Mobia Medical Inc.
- Price
- -
- -
- Market cap
- $29.91B
- $395.3M
- 1M return
- -
- +24.22%
- 1Y return
- -
- +1.74%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2026
- News (4w)
- 15
- 5
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Mobia Medical Inc.
Mobia Medical, Inc. is a medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company's Vivistim® Paired VNS System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.
Latest DXCM
- Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
- EVP Chief Legal Compliance Off Michael Jon Brown sold $141,882 worth of shares (1,700 units at $83.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 95,034 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Latest MOBI
- Mobia Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference
- SEC Form 10-Q filed by Mobia Medical Inc.
- Mobia Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Mobia Medical Reports Third Quarter 2026 Financial Results
- Mobia Medical to Participate in the 8th Annual Wolfe Research Healthcare Conference